← All trials
NCT05916391
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 19, 2023
- Primary completion
- May 1, 2025
- Completion date
- May 1, 2028
- First posted
- Jun 23, 2023
- Last posted
- Jun 23, 2023
- Enrollment
- 18
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Frontera TherapeuticsLead sponsor
- Zhengzhou UniversityCollaborator
- Zhengzhou UniversityOverall official - principal investigator
- Tianjin Medical UniversityCollaborator
- Tianjin Medical UniversityOverall official - principal investigator
- Chinese Academy of Medical SciencesCollaborator
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.